<DOC>
	<DOC>NCT02656290</DOC>
	<brief_summary>The objective of this trial is to assess the safety and effectiveness of the Edwards Pericardial Aortic Bioprosthesis Model 11000A in the pulmonary position in subjects five years or older requiring replacement of their native or prosthetic pulmonary valve.</brief_summary>
	<brief_title>COMMENCE Pulmonary: Clinical Evaluation of Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement</brief_title>
	<detailed_description>This is a prospective, Non-Randomized, Single Arm, Multicenter study. Up to one hundred (100) pulmonary valve replacement (PVR) subjects at up to ten (10) clinical sites will be enrolled to assess the safety and effectiveness of the Edwards Peri-cardial Aortic Bioprosthesis Model 11000A in the pulmonary position. The trial will include male and female subjects five year and older requiring pulmonary valve replacement of their native or prosthetic valve. Subjects will be followed for and assessed after implant for up to 5 years.</detailed_description>
	<mesh_term>Pulmonary Valve Insufficiency</mesh_term>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<criteria>1. Has pulmonary valve disease requiring pulmonary valve replacement of their native or prosthetic valve 2. Is greater than or equal to 5 years of age 3. Subject and/or subject's legal representative has provided written informed consent Exclusion criteria: A subject meeting any of the following criteria shall be excluded: 1. Requires valveinconduit procedure 2. Requires emergency surgery 3. Has acute myocardial infarction (MI) within 30 days prior to screening date 4. Has MRI or CT scan confirmed stroke, cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months (180 days) prior to screening date 5. Has hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to screening date 6. Has active endocarditis/myocarditis or endocarditis/myocarditis within 3 months prior to screening date 7. Has renal insufficiency as determined by creatinine (SCr) level ~ 2.5 mg/dL within 60 days prior to screening visit or endstage renal disease 8. Has documented leukopenia (WBC &lt; 3.5x 103/IlL), acute anemia (Hgb &lt;10.0 g/dL or 6 mmol/L), or thrombocytopenia (platelet count &lt; 50xl03/IlL) accompanied by history of bleeding diathesis or coagulopathy within 60 days prior to screening date 9. Diagnosed with abnormal calcium metabolism and/or hyperparathyroidism 10. Echocardiographic evidence of an intracardiac mass, thrombus, or vegetation 11. RVOT aneurysm unless treated during pulmonary valve replacement surgery 12. Has prior organ transplant or is currently an organ transplant candidate 13. Was previously implanted with study trial device 14. Previously implanted with an aortic, mitral, or tricuspid bioprosthetic valve, mechanical valve 15. Need for concomitant replacement of the aortic, mitral or tricuspid valves or annuloplasty ring that will remain in situ 16. Has presence of noncardiac disease limiting life expectancy to less than 12 months 17. Is Currently or has recently participated (within 6 weeks) in another investigational drug or device trial 18. Positive urine or serum pregnancy test in female subjects of childbearing potential and/or nursing mothers 19. Has left ventricular ejection fraction â‰¤20% as validated by diagnostic procedure prior to screening date or planning to become pregnant during the participation in the trial 20. Currently incarcerated or unable to give voluntary informed consent 21. Documented history of substance (drug or alcohol) abuse within the last 5 years prior to screening date IntraOp Exclusion Criterion: 22. Significant injury to the heart upon entry</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>